Century Therapeutics CFO’s Routine 266‑Share Sale Highlights Tax‑Driven Equity Management, Not a Market Signal
Century Therapeutics insider sale: Carr Douglas sold 266 shares for tax‑withholding purposes, showing routine equity‑compensation management, not a market shift.
3 minutes to read
